Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1905)	9/28/2007 12:30:16 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ALSE has been forming a little base at the 2.30 level. Today it was able to test its Aug 31- Sep 4 double top at the 2.79 level, but closed below it at 2.71, still up 6.27% on continued light volume of 15Ks. bigcharts.marketwatch.com ALSE announced on Monday that its independent Data Safety Monitoring Board has unanimously authorized expanding its PI/IIa trial of Cethrin in acute spinal cord injury. Authorization to administer a 9 mg dose in SCI had been given by the FDA in June & earlier by the Canadian Health. ALSE expects to complete enrollment in the trial by the end of the Yr.They are planning a PIIb/III to begin enrollment in early 2008. Cethrin is a recombinant protein intended to facilitate the re-growth of axons.It is delivered by a single application in patients that undergo decompression/stabilization surgery after spinal injury.It has been designated as an Orphan Drug by the FDA. In PI/IIa, Cethrin was given to patients that had suffered a complete thoracic or cervical injury & had no sensory or motor function below the level of the SCI. In the 37 patients that were treated,Cethrin was well tolerated & the treated patients showed better results, specially the patients that had sustained cervical injuries.(That last group showed a more pronounced response,6 to 7x greater than the full patient group treated with the standard of care reported in the literature.) The stock needs to close above 2.95 in order to get off from the DT coming from its June H at 3.52 bigcharts.marketwatch.com And then it would have to deal with the Aug-Sep 2006 double top at the 4.24 level bigcharts.marketwatch.com But if ALSE can get good results on its planned trials, which would be very good for patients with spinal cord injuries,the stock has plenty of room to run, since the 2000 H was 80.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1905)	1/7/2008 1:25:03 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANX is up 11.66%, but it still needs to close its Oct 1 DG.<g> bigcharts.marketwatch.com Its lead product candidate, ANX-510,is in PIII & PIIb trials for the treatment of metastatic colorectal Ca & in a PII for the treatment of advanced breast Ca. Its ANX-530,is in a clinical trial for the treatment of NSCLC Besides those two, ANX also has ANX-513, which is a paclitaxel emulsion for possible treatment of ovarian & NSCLC; ANX-514, which is a docetaxel emulsion for possible treatment of breast, NSCLC, prostate & gastric Cas. It also has some drugs for possible treatment of IDs, like its ANX-201 for HIV; ANX-015, which is a clarithromycin emulsion,an IV formulation of clarithromycin &ANX-016, whichb is a vancomycin emulsion. ANX trades around 1.8xBV; the insiders reportedly hold > 15%; it doesn't have significant LTD, but has a negative CF around $0.35 & is expected to have persistent losses in 2007 & 2008 around $0.25/shr. If ANX could get to close its Oct DG & trade up to the $1 level, it would be a good % gain from present levels.<g> bigcharts.marketwatch.com Bernard